Introducing the FIRST cohort

Setting up the prospective multidisciplinary cohort IMMINeNT

FIRST is a prospective cohort of patients with atopic dermatitis part of the multidisciplinary prospective cohort IMMINeNT. 

logo IMMINeNT qui devient PRECISE

Chronic immune-mediated inflammatory diseases (CIIDs) are caused by hyperactivity and dysfunction of the immune system (normally in charge of defending our body) which becomes deleterious. They most often affect young patients, and although they have little impact on life expectancy, they induce high morbidity and significantly impair the quality of life of patients with professional, social and emotional impact. Indeed, these diseases are characterised by their duration, their progressive nature, often associated with disability, and by the threat of serious complications, which may be induced by the various therapies proposed, and which have a considerable impact on daily life.

Beyond their impact, CIIDs have many common characteristics such as their mechanisms and treatments, called "targeted therapies". These drugs have recently improved patient care and quality of life. However, much remains to be done in clinical, therapeutic and basic research.

In order to respond to all of these challenges, the FHU IMMINeNT project or "Fédératif Hospitalo-Universitaire IMmune-Mediated INflammatory diseases aNd Targeted Therapies" project, followed by the FHU PRECISE PREcision health in Complex Immune-mediated inflammatory diseaSEs project, were approved after an international assessment. They are based in particular on the constitution of a clinical and biological database called the IMMINeNT cohort, linked to a biobank. This large prospective and multidisciplinary cohort, whose constitution is the object of this project, will provide the transdisciplinary aspect for physiopathological, clinical and therapeutic studies. The main challenges of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with CIIDs.

The IMMINeNT project is coordinated by Pr David Launay, under the responsibility of Pr Delphine STAUMONT-SALLE for the atopic dermatitis cohort.

The project is funded by the CHRU of Lille, the University of Lille and the Société Française de Dermatologie (SFD) fund for the AD cohort. 


The aim of this project is to set up a prospective clinical and biological database, the "IMMINeNT cohort", of adult CIIDs patients followed up in one of the participating centres for the following diseases: angioedema, severe atopic dermatitis, lupus, systemic scleroderma, multiple sclerosis (MS), severe asthma, psoriatic arthritis, Behçet's disease.

The main scientific objectives of this database are to identify new biomarkers and determinants associated with disease activity and severity, quality of life and infectious risk in CIIDs patients, as well as to carry out medico-economic studies using medico-administrative databases. The inclusion of patients with different CIIDs will allow transdisciplinary studies to be conducted.

Inclusion criteria:

  • Men and/or women
  • Adults aged 18 years and over
  • Patient followed up for atopic dermatitis in one of the participating centres,
  • having social insurance
  • Have the ability to understand the study requirements, provide written informed consent, and comply with the study data collection procedures

Non inclusion criteria:

  • Pregnant or breastfeeding women
  • Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage
  • Persons deprived of liberty
  • Persons who are under 18 or protected adults
  • Persons who have refused or are unable to give informed consent
  • Persons in emergency situations

Patients are included at the initiation of systemic therapy for their atopic dermatitis. 

Data collection is done as part of routine care, except for the collection of:

  • Quality of life score assessed for all CIIDs by the SF-12 scale
  • Blood sampling for biological collection


What are the expected outcomes of the FIRST cohort

  • Identification of biomarkers, potential targets for new treatments in patients with atopic dermatitis,
  • Better knowledge of the factors influencing morbidity and mortality and quality of life in patients with atopic dermatitis.



Updated on 11 August 2023